Posted by Michael Wonder on 22 Nov 2020
ICER publishes final report and policy recommendations for haemophilia A therapies
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor VIII prophylaxis; emicizumab is also cost saving, but only because factor VIII prices remain so high.
The Institute for Clinical and Economic Review today released an Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of valoctocogene roxaparvovec (Roctavian, BioMarin Pharmaceutical) and emicizumab (Hemlibra, Genentech) for the treatment of hemophilia A.
